Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 21:30 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Rebalancing the Serotonergic System in Cocaine Dependence
NCT03266939 · Mclean Hospital · PHASE1 · withdrawn · last registry update 2025-10-20 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Study was never funded because lorcaserin was pulled from FDA approval” | – | Registry record, Mclean Hospital |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against HTR2C within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2026-10-08Results posted on the registry: Corey Hawes, Cyproheptadine + Olanzapine (NCT06175273)
- 2026-09-14Also stopped (terminated): Denovo Biopharma LLC, LY2140023 + Olanzapine (NCT01129674)
- 2026-09-09Also stopped (terminated): Apsen Farmaceutica S.A., Fixed Dose Combination + Etodolac (NCT03127592)
- 2026-09-02Results posted on the registry: The Guthrie Clinic, OLA group: Olanzapine + DEX group: Dexamethasone (NCT05590923)
- 2026-09-02Also stopped (terminated): The Guthrie Clinic, OLA group: Olanzapine + DEX group: Dexamethasone (NCT05590923)
- 2026-08-12Phase 3 first posted: All India Institute of Medical Sciences, Bhubaneswar, quetiapine (NCT07760168)
- 2026-08-12Results posted on the registry: Apnimed, AD109 + AD504 (NCT05071612)
- 2026-07-28Also stopped (withdrawn): Icahn School of Medicine at Mount Sinai, Clonazepam + Olanzapine (NCT06133114)
- 2026-07-21Phase 3 first posted: Second Affiliated Hospital, Zhejiang University, School of Medicine, Auricular point stimulation plus dexamethasone + Standard pharmacologic antiemetic regimen (NCT07716189)
- 2026-07-21Phase 3 first posted: Second Affiliated Hospital, Zhejiang University, School of Medicine, Auricular point stimulation plus dexamethasone + Standard pharmacologic antiemetic regimen (NCT07716228)
- 2026-07-21Phase 3 first posted: Second Affiliated Hospital, Zhejiang University, School of Medicine, Auricular point stimulation plus dexamethasone + Standard pharmacologic antiemetic regimen (NCT07716176)
- 2026-07-16Results posted on the registry: Yale University, Olanzapine + Placebo (NCT05676294)
- 2026-06-30Results posted on the registry: Teva Branded Pharmaceutical Products R&D LLC, TV-44749 318mg + Oral Olanzapine 10mg/day (NCT06253546)
- 2026-06-08Phase 3 first posted: Blokhin's Russian Cancer Research Center, OLANZapine 2.5 MG (NCT07633236)
- 2026-05-26Phase 3 first posted: University Medical Center Groningen, a drug against HTR2C (NCT07606014)
- 2026-05-22Also stopped (terminated): OrthoCarolina Research Institute, Inc., a drug against HTR2C (NCT02202369)
- 2026-05-04Phase 3 first posted: Minerva Neurosciences, Roluperidone + risperidone (NCT07565428)
- 2026-05-04Also stopped (withdrawn): University of Southern California, Trazodone + Quetiapine (NCT05085808)
- 2026-02-25Also stopped (terminated): Ohio State University, Clozapine + Antipsychotics,Other (non-Clozapine) (NCT05741502)
- 2026-02-17Phase 3 first posted: The Affiliated People's Hospital of Ningbo University, Fosaprepitant + Fosaprepitant (NCT07413809)
- 2026-02-11Phase 3 first posted: University of Michigan, Cyclobenzaprine (NCT07404397)
- 2026-01-26Results posted on the registry: Teva Branded Pharmaceutical Products R&D LLC, Olanzapine Extended Release + Olanzapine Immediate Release (NCT06319170)
- 2026-01-09Results posted on the registry: Teva Branded Pharmaceutical Products R&D LLC, TV-44749 + Placebo (NCT05693935)
- 2025-12-31Results posted on the registry: Otsuka Pharmaceutical Development & Commercialization, Inc., SEP363856 + quetiapine XR (NCT04115319)
- 2025-12-22Phase 3 first posted: University of California, San Francisco, Pharmacologic Pain Management (NCT07296770)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision